

BAB VI

TINJAUAN PUSTAKA

- Abedi, F., Wickremasinghe, S., Richardson, A.J., Islam, A.F., Guymer, R.H., Baird, P.N., 2013 “Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration”. *Ophthalmology* ;120(8):1641–1648
- Amoaku, W.M., Chakravarthy, U., Gale, R., 2015, “Defining response to anti-VEGF therapies in neovascular AMD”, *Eye (Lond)* ;29(6): 721–731.
- Arjamaa, O., Minn, H., 2012, “ Resistance, not tachyphylaxis or tolerance”, *Br. J. Ophthalmol* ;96(8):1153–1154.
- Awata, T., Neda, T., Iizuka, H., 2004, “ Endothelial nitric oxide synthase gene is associated with diabetic macular edema in type 2 diabetes. *Diabetes Care*; 27:2184–90.
- Bakall, B., Folk, J.C., Boldt, H.C., 2013, “ Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab”. *Am J Ophthalmol* ;156(1):15–22.e11.
- Binder, S., 2012, “Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?”, *Br. J. Ophthalmol* ;96(1):1–2.
- Broadhead, G.K., Hong, T., Chang, A.A., 2014, “ Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration”, *Acta Ophthalmol* ;92(8): 713–723.
- Boltz A., Ruiss M., Jonas J.B., Tao Y., Rensch F., Weger M., Garhöfer G., Frantal S, El-Shabrawi Y., Schmetterer L., “ Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration”. *Ophthalmology* 2012; 119:1615–1620.
- Boekhorn S., Isaacs A., Uitterlinden A., Duijn C., Hofman A., de Jong P.T, Vingerling J.R., 2008. “Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. *Ophthalmology* 2008;115:1899–1903
- Brown, D.M., Kaiser, P.K., Michels, M., Soubrane, G., Heier, J.S., Kim, R.Y., Judy P., Schneider, S., ANCHOR Study Group . 2009. "Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study." *Ophthalmology* 116.1 : 57-65.
- Carlos A. Moreira-Neto, Eric M. Moul, James G. Fujimoto, Nadia K. Waheed, Daniela Ferrara, "Choriocapillaris Loss in Advanced Age-Related Macular

Degeneration", *Journal of Ophthalmology*, vol. 2018, Article ID 8125267, 6 pages, 2018. <https://doi.org/10.1155/2018/8125267>

- Chakravarthy, U., Bezlyak, V., Sagkriotis, A., et al, 2019, “ Effectiveness of continued ranibizumab therapy in neovascular age-related macular degeneration versus switch to aflibercept: real world evidence”, *Ophthalmol Retina* ;3(1):8-15.e1.
- Chen, H., Yu, K.D., Xu, G.Z., 2012,” Association between variant Y402H in agerelated macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis”. *PLoS One* ;7(8): e42464.
- Churchill, A.J., Carter, J.G., Lovell, H.C., Ramsden, C., Turner, S.J., Yeung, A., Escardo, J., Atan, D., 2006,” VEGF polymorphisms are associated with neovascular age-related macular degeneration”. *Hum. Mol. Genet*;15:2955–2961.
- Ciucci, F., Ioele, G., Bardocci, A., Lofoco, G., Antonelli, B., Gaetano, C.D., Polimantini, G., Luca, M.D., Ragno, G., Gattegna, R., 2022. “ Central retinal thickness fluctuations in patients treated with anti-VEGF for neovascular age related macular degeneration”. *Eur J Ophthalmol*. 2022 Jul;32(4):2388-2394. doi: 10.1177/11206721211037820. Epub 2021 Aug 14. PMID: 34392710.
- Coleman, H.R., Chan, C.C., Ferris, F.L III, Chew, E.Y., 2008, “Age-related macular degeneration”. *Lancet* 2008;372:1835–1845.
- De Jong, P.T., 2006, “Age-related macular degeneration”, *N. Engl. J. Med* ;355:1474–1485.
- De Jong, P.T., Bockhoorn, S.S., Vingerling, J.R., Uitterlinden, A.G., Hoffman, A., 2007, “Polymorphisms in the Vascular Endothelial Growth Factor Gene and Risk of Aging Macula Disorder: The Rotterdam Study”, *Invest. Ophthalmol. Vis. Sci*;48:E-2119.
- Ellabban A.A., Tsujikawa A., Ogino K, et al. 2012. “ Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization”. *Clin Ophthalmol* 2012;6:837-44
- Esfandiary, H, Chakravarthy, U., Patterson, C, Young, I., dan Hughes, A.E., 2005, “Association study of detoxification genes in age related macular degeneration,” *British Journal of Ophthalmology*, vol. 89, no. 4, pp. 470–474, 2005.
- Falavarjani, K.G., Nguyen, Q. D., 2013. “Adverse events and complications associated with intravitreal injections of anti- VEGF agents: a review of literature”. *Eye (Lond)* ;27 (7) :787 – 94
- Ferrara, N., 2000, “Vascular endothelial growth factor and the regulation of angiogenesis”, *Recent Prog Horm Res* ;55:15–35; discussion 35–6.

- Ferrara, N., Gerber, H.P., 2001 “The role of vascular endothelial growth factor in angiogenesis. *Acta Haematol*” ;106:148–56.
- Forooghian, F., Cukras, C., Meyerle, C.B., Chew, E.Y., Wong, W.T., 2009, “Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration”. *Retina* ;29(6):723–731.
- Fung, A.E, Rosenfield, P.J, Reichel E., 2006. “The international intravitreal bevacizumab safety survey using the internet to assess drug safety worldwide”. *Br J Ophthalmol* 2006;90(11):1344–9
- Haines., J.L, Schnetz-Boutaud, N., Schmidt, S., Scott, W.K., Agarwal, A., Postel E.A, Olson L, Kenealy, S.J., Hauser, M., Gilbert, J.R., Pericak-Vance, M.A., 2006, “Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6”. *Invest. Ophthalmol. Vis. Sci* ;47:329–335.
- Haines, J.L., Schnetz-Boutaud, N., Schmidt, S., 2006,” Functional Candidate Genes in Age-related Macular Degeneration: significant association with VEGF, VLDLR, and LRP6”. *Invest Ophthalmol Vis Sci*;47:329–35.
- Holmes, K., Roberts, O.L., Thomas, A.M., Cros, M.J., 2007. ” Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition”. *Cellular Signalling. Volume 19, Issue 10, October 2007, Pages 2003-2012*
- Hu, Z., Xie, P., Ding, Y., Yuan, D., Liu, Q., 2015 “ Association between variants A69S in ARMS2 gene and response to treatment of exudative AMD: a meta-analysis”. *Br J Ophthalmol* ;99(5):593–598
- Jan S, Nazim M, Karim S, Hussain Z. 2016. Intravitreal Bevacizumab: Indications And Complications. *J Ayub Med Coll Abbottabad*. 2016 Apr-Jun;28(2):364-368. PMID: 28718542.
- Jager, R.D., Mieler, W.F., Miller, J.W., 2008, “Age-related macular degeneration”. *N. Engl. J. Med*;358:2606– 2617.
- Kaiser, J., 2008, “Genetics First gene for severe dry macular degeneration”. *Science*;321:1146–1147.
- Kaiser, P.K., 2006, “Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases”. *Am J Ophthalmol*;142:660–8.
- Kaiser, P.K., 2013, “ Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline”, *Ophthalmology* ;120(5 suppl): S11–S15.
- Liesegang, T. J., Gregory, L. S., & Cantor, L. B. 2017. *Basic and Clinical Science Course-American Academy of Ophthalmology. Retina and Vitreous 12*, Amerika.

- Lazzeri S., Figus M., Orlandi P, et al. 2013. “ VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration”. *Pharmacogenomics* 2013;14:623–30
- Lin, J.M., Wan, L., Tsai, Y.Y., Lin, H.J., Tsai, Y., Lee, C.C., Tsai, C.H., Tseng, S.H., Tsai, F.J., 2008, “Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration”. *Am. J. Ophthalmol* 2008;145:1045–1051
- Martin, D.F., Maguire, M.G., Fine, S.L., et al, 2012,” Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results”, *Ophthalmology*.;119(7):1388-1398.
- McKibbin M., Ali M., Bansal S., Baxter P.D., West K., Williams G., Cassidy F., Inglehearn C.F., 2012. “ CFH , VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular agerelated macular degeneration”. *Br J Ophthalmol* 2012;96:208–212
- Morgan, D.J. and DeAngelis, M.M. , 2015, “Differential Gene Expression in Age-Related Macular Degeneration”. *Cold Spring Harb Perspect Med*, 5, a017210.
- Nakata I., Yamashiro K., Nakanishi H., Tsujikawa A., Otani A., Yoshimura N., 2011. “ VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration”. *Jpn J Ophthalmol* 2011;55:435–443
- Park, U. C., Shin, J. Y., Kim, S. J., Shin, E. S., Lee, J. E., Kim, S., Yu, H. G. 2012. “Genetic factors associated with early response to intravitreal ranibizumab treatment in Korean neovascular age-related macular degeneration patients”. *Investigative Ophthalmology & Visual Science*, 53(14), 3327-3327.
- Pennington, K.L., and DeAngelis, M.M., 2015, “Epigenetic Mechanisms of the Aging Human Retina”. *J Exp Neurosci*, 9, 51–79.
- Rusnati, M., Presta, M., 2007, “ Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies”, *Curr. Pharm. Des* ;13(20):2025–2044.
- Richardson, A.J., Islam, F.M., Guymer, R.H., Cain, M., Baird, P.N., 2007, “A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration”. *Mol. Vis* 2007;13:2148–2152.
- Sacca, S. C., Bolognesi, C., Battistella, A., Bagnis, A., dan Izzotti, A., 2009, “Gene-environment interactions in ocular diseases,” *Mutation Research—*

- Fundamental and Molecular Mechanisms of Mutagenesis, vol. 667, no. 1-2, pp. 98–117.
- Sizmaz, S., Kucukerdonmez, C., Kal A., Pinarci, E.Y., Canan H, Yilmaz G., 2014. “Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab”. *Eur J Ophthalmol.* 2014 Nov-Dec;24(6):904-10. doi: 10.5301/ejo.5000478. Epub 2014 May 5. PMID: 24803153.
- Sogawa K., Nagaoka T., Takahashi A., 2012. “ Relationship between choroidal thickness and choroidal circulation in healthy young subjects” . *Am J Ophthalmol* 2012;153: 1129-32.
- Swaroop, A., Branham, K. E. H., Chen, W., dan Abecasis, ., 2007, “Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits,” *Human Molecular Genetics*, vol. 16, no. 2, pp. R174–R182.
- Smith, S.R., Tong, Z., Constantine, R., Brinton, E., Cameron, J., Gibbs, D., Schneider, S., Harmon, J., Yang, Z., Zhang, K., 2007, “Vascular endothelial growth factor (VEGF) polymorphisms and their association with age-related macular degeneration”, *Invest. Ophthalmol. Vis. Sci:E-* 2097.
- Tannan, A., C. Li, and T. S. Stevens. 2010. "Predicting treatment outcomes in patients with newly diagnosed exudative age-related macular degeneration based on initial presentation." *Investigative Ophthalmology & Visual Science* 51.13 (2010): 907-907.
- Ting, A. Y., Lee, T. K., MacDonald, I.M., 2009, “Genetics of agerelated macular degeneration,” *Current Opinion in Ophthalmology*, vol. 20, pp. 369–376.
- Tranos, P., Vacalis, A., Asteriadis, S., 2013,” Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration”. *Drug Des Devel Ther* ;7:485–490
- Veloso, C,E,R., Almeida, L,N,F., Recchia,F,R., Pelayes,D., Nehemy, M,B.,2014. “VEGF Gene Polymorphism and Response to Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration”. *Ophthalmic Res* 2014;51:1–8 DOI: 10.1159/000354328
- Wylegala, E., Teper, S.J., 2007, “ VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in agerelated macular degeneration treatment”, *Klin. Oczna* ;109:97–100.
- Wu, E., Palmer, N., Tian, Z., 2008, “ Comprehensive dissection of PDGFPDGFR signaling pathways in PDGFR genetically defined cells”. *PLoS One* ;3(11):e3794.

- Yates, J.R.W., dan Moore, A. T., 2000, “Genetic susceptibility to age related macular degeneration,” *Journal of Medical Genetics*, vol. 37, no. 2, pp. 83–87.
- Yildiz, K.B., Ozdek, S., Ergun, M.A., Ergun, S., Tuncay, Y.F., dan Elbeg, S., 2016 “CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration”. *Ophthalmic Res.*, 56, 132–138.